RxDoctor Payments DataLook up a doctor →

Hitendra Patel, MD

Pulmonary Disease · Marietta, GANPI 1316962541

Payments from drug & device makers

$104,086in general payments, 2019–2025

Across 551 payments — averaging $188.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$92K
  • Inspire Medical Systems, Inc.$2K
  • ZOLL Respicardia, Inc.$2K
  • GSK$1K
  • Jazz Pharmaceuticals Inc.$1K
  • Itamar Medical Inc$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$7,8758%
  • Speaking & faculty fees$79,87577%
  • Travel & lodging$6,5936%
  • Food & beverage$9,3809%
  • Education$3640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,086 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$154,115
Medicare patients
664
Services billed
1,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate21$412,706
Trelegy ElliptaFluticasone/Umeclidin/Vilanter396$307,886
OfevNintedanib Esylate13$172,330
TezspireTezepelumab-Ekko31$128,169
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$24,278
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$21,910
Advair HfaFluticasone Propion/Salmeterol34$15,144
Breo ElliptaFluticasone/Vilanterol27$14,667
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,876
Fluticasone-SalmeterolFluticasone Propion/Salmeterol62$9,666
Doxepin Hcl93$4,258
Arnuity ElliptaFluticasone Furoate14$4,124
Albuterol Sulfate HfaAlbuterol Sulfate144$4,040
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,904
SymbicortBudesonide/Formoterol Fumarate13$2,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$1,255$336,553454 claims
Boehringer IngelheimOfev, Stiolto Respimat$451$196,60859 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$976$152,70075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →